Penelope J Hallett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6634668/publications.pdf

Version: 2024-02-01

45 papers	4,016 citations	147566 31 h-index	233125 45 g-index
46 all docs	46 docs citations	46 times ranked	5462 citing authors

#	Article	IF	Citations
1	Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15921-15926.	3.3	441
2	Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nature Medicine, 2008, 14, 507-509.	15.2	410
3	Successful Function of Autologous iPSC-Derived Dopamine Neurons following Transplantation in a Non-Human Primate Model of Parkinsonâ€™s Disease. Cell Stem Cell, 2015, 16, 269-274.	5.2	271
4	Rationale for and use of NMDA receptor antagonists in Parkinson's disease. , 2004, 102, 155-174.		204
5	Improved Cell Therapy Protocols for Parkinson's Disease Based on Differentiation Efficiency and Safety of hESC-, hiPSC-, and Non-Human Primate iPSC-Derived Dopaminergic Neurons. Stem Cells, 2013, 31, 1548-1562.	1.4	197
6	Dopamine D1 Activation Potentiates Striatal NMDA Receptors by Tyrosine Phosphorylation-Dependent Subunit Trafficking. Journal of Neuroscience, 2006, 26, 4690-4700.	1.7	193
7	Progressive decline of glucocerebrosidase in aging and <scp>P</scp> arkinson's disease. Annals of Clinical and Translational Neurology, 2015, 2, 433-438.	1.7	165
8	Long-Term Health of Dopaminergic Neuron Transplants in Parkinson's Disease Patients. Cell Reports, 2014, 7, 1755-1761.	2.9	133
9	Glucocerebrosidase gene therapy prevents Î±-synucleinopathy of midbrain dopamine neurons. Neurobiology of Disease, 2015, 82, 495-503.	2.1	120
10	Sustained Systemic Glucocerebrosidase Inhibition Induces Brain Î±-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. Antioxidants and Redox Signaling, 2015, 23, 550-564.	2.5	118
11	Reduced sphingolipid hydrolase activities, substrate accumulation and ganglioside decline in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2019, 14, 40.	4.4	100
12	Alpha-synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits. Neurobiology of Disease, 2012, 47, 258-267.	2.1	93
13	Striatal histone modifications in models of levodopaâ€induced dyskinesia. Journal of Neurochemistry, 2008, 106, 486-494.	2.1	92
14	The Toll-Like Receptor-3 Agonist Polyinosinic:Polycytidylic Acid Triggers Nigrostriatal Dopaminergic Degeneration. Journal of Neuroscience, 2010, 30, 16091-16101.	1.7	89
15	The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. Neurobiology of Disease, 2018, 120, 1-11.	2.1	85
16	Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Human Molecular Genetics, 2014, 23, 4510-4527.	1.4	82
17	Inhibition of the Dopamine D1 Receptor Signaling by PSD-95. Journal of Biological Chemistry, 2007, 282, 15778-15789.	1.6	81
18	Biochemical Fractionation of Brain Tissue for Studies of Receptor Distribution and Trafficking. Current Protocols in Neuroscience, 2008, 42, Unit 1.16.	2.6	78

#	Article	IF	Citations
19	Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinsonâ€™s disease. Journal of Neuroinflammation, 2019, 16, 153.	3.1	76
20	Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neuroscience Letters, 2014, 576, 73-78.	1.0	74
21	PSD-95 Uncouples Dopamineâ€“Glutamate Interaction in the D₁/PSD-95/NMDA Receptor Complex. Journal of Neuroscience, 2009, 29, 2948-2960.	1.7	72
22	Enhanced ubiquitin-dependent degradation by Nedd4 protects against Î±-synuclein accumulation and toxicity in animal models of Parkinson's disease. Neurobiology of Disease, 2014, 64, 79-87.	2.1	71
23	Glycosphingolipid levels and glucocerebrosidase activity are altered in normal aging of the mouse brain. Neurobiology of Aging, 2018, 67, 189-200.	1.5	66
24	Synaptic recruitment of AMPA glutamate receptor subunits in levodopaâ€induced dyskinesia in the MPTPâ€lesioned nonhuman primate. Synapse, 2010, 64, 177-180.	0.6	65
25	Fibroblast Biomarkers of Sporadic Parkinsonâ€™s Disease and LRRK2 Kinase Inhibition. Molecular Neurobiology, 2016, 53, 5161-5177.	1.9	60
26	Cell type-specific lipid storage changes in Parkinsonâ€™s disease patient brains are recapitulated by experimental glycolipid disturbance. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27646-27654.	3.3	59
27	Neurite Collapse and Altered ER Ca2+ Control in Human Parkinson Disease Patient iPSC-Derived Neurons with LRRK2 G2019S Mutation. Stem Cell Reports, 2019, 12, 29-41.	2.3	57
28	A Nurr1 Agonist Causes Neuroprotection in a Parkinsonâ€™s Disease Lesion Model Primed with the Toll-Like Receptor 3 dsRNA Inflammatory Stimulant Poly(I:C). PLoS ONE, 2015, 10, e0121072.	1.1	53
29	Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 22474-22479.	3.3	50
30	Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinsonâ€™s disease patient fibroblasts. Human Molecular Genetics, 2019, 28, 3232-3243.	1.4	48
31	Development of Histocompatible Primateâ€induced Pluripotent Stem Cells for Neural Transplantation. Stem Cells, 2011, 29, 1052-1063.	1.4	41
32	Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Molecular and Cellular Neurosciences, 2012, 49, 230-239.	1.0	41
33	Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice. Molecular Therapy - Nucleic Acids, 2020, 21, 623-635.	2.3	33
34	The bloodâ€“brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primatesâ€”Evidence from in vivo neuroimaging studies. Neurobiology of Disease, 2009, 35, 348-351.	2.1	29
35	Advantages and Recent Developments of Autologous Cell Therapy for Parkinsonâ€™s Disease Patients. Frontiers in Cellular Neuroscience, 2020, 14, 58.	1.8	27
36	Lipid-dependent deposition of alpha-synuclein and Tau on neuronal Secretogranin II-positive vesicular membranes with age. Scientific Reports, 2018, 8, 15207.	1.6	24

#	Article	IF	Citations
37	Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. Movement Disorders, 2007, 22, 28-40.	2.2	22
38	Novel Results and Concepts Emerging From Lipid Cell Biology Relevant to Degenerative Brain Aging and Disease. Frontiers in Neurology, 2019, 10, 1053.	1.1	21
39	Glycosphingolipid metabolism and its role in ageing and Parkinsonâ€™s disease. Glycoconjugate Journal, 2022, 39, 39-53.	1.4	18
40	Upregulating Î²-hexosaminidase activity in rodents prevents Î±-synuclein lipid associations and protects dopaminergic neurons from Î±-synuclein-mediated neurotoxicity. Acta Neuropathologica Communications, 2020, 8, 127.	2.4	17
41	Fibroblasts from idiopathic Parkinsonâ€™s disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2. Molecular Brain, 2021, 14, 16.	1.3	13
42	ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress. Experimental Neurology, 2014, 261, 217-229.	2.0	12
43	Seq-ing Markers of Midbrain Dopamine Neurons. Cell Stem Cell, 2017, 20, 11-12.	5.2	6
44	Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson's disease genetic risk. International Review of Neurobiology, 2020, 154, 279-302.	0.9	5
45	No evidence for disease-like processes in fetal transplants. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, E104; author reply E105.	3.3	2